Prevencio specializes in cardiovascular multi-protein biomarker tests for Research Use Only (RUO) in Pharmaceutical, Medical Device and Investigator-initiated clinical research

Prevencio's HART blood tests for cardiovascular disease employ artificial intelligence (AI), multi-proteins, and proprietary algorithms to derive a score for diagnosis of cardiovascular disease or a predictive risk for an adverse event

Examples of Research Use testing applications of Prevencio HART tests

Diagnoses obstructive coronary artery disease diagnosis (≥70%); significantly more accurate than standard-of-care stress tests. HART CAD includes biomarkers of plaque inflammation (Midkine), dyslipidemia (Apolipoprotein C-1), glucose and fatty metabolism (Adiponectin) and cardiorenal syndrome (Kidney Injury Molecule-1; KIM-1), as well as two clinical variables (male sex and history of coronary angioplasty and/or coronary stent). 

Diagnoses obstructive peripheral artery disease of the lower extremities (≥50%). HART PAD includes biomarkers of Kidney Injury Molecule-1 (KIM-1), Osteopontin, and Adiponectin.

Predicts the 1-year risk of heart attack, stroke or cardiac death; significantly more accurate than standard of care risk scores. HART CVE includes biomarkers of plaque inflammation & calcification (Osteopontin), plaque rupture & extracellular degradation (Tissue Inhibitor of Metalloproteinase-1; TIMP-1), myocardial wall stress/ischemia (NT-proBNP), and cardiorenal syndrome (Kidney Injury Molecule-1; KIM-1). 

Diagnoses severity of aortic valve stenosis. HART AS includes biomarkers of myocardial wall stress/ischemia (NT-pro-BNP), platelet adhesion (von Willebrand Factor), and calcification (Fetuin-A), as well as one clinical variable (Age).

Identifies the risk of amputation. HART AMP includes biomarkers of cardiorenal syndrome and vascular calcification, as well as one clinical factor (History of Diabetes). 

The HART tests have not been cleared by the FDA and are being offered for Research Use Only (RUO)